Lungpacer Medical has submitted a premarket approval (PMA) application to the US FDA for its AeroPace System. AeroPace is a minimally invasive transvenous diaphragm strengthening neurostimulation therapy designed for quicker liberation from mechanical ventilation.
Lungpacer Medical has submitted a premarket approval (PMA) application to the US FDA for its AeroPace System. AeroPace is a minimally invasive transvenous diaphragm strengthening neurostimulation therapy designed for quicker liberation from mechanical ventilation.
Read More
Lungpacer Medical is introducing its AeroPace Diaphragm Strengthening System into the RESCUE 3 pivotal clinical study, which is researching faster ventilator independence.
Read More
The Lungpacer system is designed to activate the diaphragm using a temporary, minimally invasive, transvascular nerve stimulation approach.
Read More
